Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Alto Neuroscience (ANRO) Return on Equity (2023 - 2026)

Alto Neuroscience has reported Return on Equity over the past 4 years, most recently at 0.0% for Q1 2026.

  • Quarterly results put Return on Equity at 0.0% for Q1 2026, changed 0.0% from a year ago — trailing twelve months through Mar 2026 was 0.0% (changed 0.0% YoY), and the annual figure for FY2025 was 0.0%, up 1.0%.
  • Return on Equity reached 0.0% in Q1 2026 per ANRO's latest filing, up from 0.0% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.01% in Q4 2023 and bottomed at 0.01% in Q1 2024.
  • Median Return on Equity over the past 4 years was 0.0% (2024), compared with a mean of 0.0%.
  • The largest annual shift saw Return on Equity fell -1bps in 2024 before it changed 0bps in 2025.
  • Over 4 years, Return on Equity stood at 0.01% in 2023, then crashed by -170bps to 0.0% in 2024, then dropped by -23bps to 0.0% in 2025, then increased by 21bps to 0.0% in 2026.
  • Business Quant data shows Return on Equity for ANRO at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.01% in Q3 2025.